For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are “clinical, financial, and regulatory considerations” that must be reviewed before it will take that step.
Not surprisingly, though, what the largest pharmacy benefits manager in the U.S. simply wants is a much lower price, according to email sent this week by a company executive to an AIDS patient advocacy group.
At issue is Yeztugo, a groundbreaking medicine that was approved last June by the U.S. Food and Drug Administration. Clinical trials showed the twice-a-year injectable was highly effective in preventing the infectious disease, prompting enthusiasm about combating HIV globally. But the $28,000 price tag in the U.S. has raised concern about affordability.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.